CA2241952A1 - Immunogenes cellulaires utiles en tant que vaccins contre le cancer - Google Patents
Immunogenes cellulaires utiles en tant que vaccins contre le cancer Download PDFInfo
- Publication number
- CA2241952A1 CA2241952A1 CA002241952A CA2241952A CA2241952A1 CA 2241952 A1 CA2241952 A1 CA 2241952A1 CA 002241952 A CA002241952 A CA 002241952A CA 2241952 A CA2241952 A CA 2241952A CA 2241952 A1 CA2241952 A1 CA 2241952A1
- Authority
- CA
- Canada
- Prior art keywords
- oncogene
- transgene
- host
- proto
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000001413 cellular effect Effects 0.000 title claims abstract description 29
- 238000009566 cancer vaccine Methods 0.000 title description 4
- 229940022399 cancer vaccine Drugs 0.000 title description 4
- 210000004027 cell Anatomy 0.000 claims abstract description 167
- 108700020978 Proto-Oncogene Proteins 0.000 claims abstract description 116
- 102000052575 Proto-Oncogene Human genes 0.000 claims abstract description 111
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 90
- 108700019146 Transgenes Proteins 0.000 claims abstract description 79
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 76
- 108700020796 Oncogene Proteins 0.000 claims abstract description 64
- 230000002018 overexpression Effects 0.000 claims abstract description 46
- 230000014509 gene expression Effects 0.000 claims abstract description 35
- 201000011510 cancer Diseases 0.000 claims abstract description 29
- 230000002163 immunogen Effects 0.000 claims abstract description 25
- 230000001177 retroviral effect Effects 0.000 claims abstract description 25
- 230000000694 effects Effects 0.000 claims abstract description 16
- 230000003053 immunization Effects 0.000 claims abstract description 11
- 108020004414 DNA Proteins 0.000 claims description 62
- 238000000034 method Methods 0.000 claims description 49
- 102000001332 SRC Human genes 0.000 claims description 28
- 108060006706 SRC Proteins 0.000 claims description 28
- 101710135898 Myc proto-oncogene protein Proteins 0.000 claims description 27
- 102100038895 Myc proto-oncogene protein Human genes 0.000 claims description 27
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 27
- 101710150448 Transcriptional regulator Myc Proteins 0.000 claims description 27
- 230000037430 deletion Effects 0.000 claims description 27
- 238000012217 deletion Methods 0.000 claims description 27
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 25
- 230000035772 mutation Effects 0.000 claims description 24
- 210000002950 fibroblast Anatomy 0.000 claims description 22
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 claims description 14
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 claims description 13
- 101100162366 Caenorhabditis elegans akt-2 gene Proteins 0.000 claims description 10
- 230000009466 transformation Effects 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 108010087776 Proto-Oncogene Proteins c-myb Proteins 0.000 claims description 8
- 108010021833 Proto-Oncogene Proteins c-yes Proteins 0.000 claims description 6
- 102000007696 Proto-Oncogene Proteins c-yes Human genes 0.000 claims description 6
- -1 c-ras Proteins 0.000 claims description 6
- 102000009096 Proto-Oncogene Proteins c-myb Human genes 0.000 claims 3
- 230000036210 malignancy Effects 0.000 abstract 1
- 210000001626 skin fibroblast Anatomy 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 62
- 238000012360 testing method Methods 0.000 description 54
- 239000000047 product Substances 0.000 description 44
- 102000004196 processed proteins & peptides Human genes 0.000 description 39
- 241000287828 Gallus gallus Species 0.000 description 37
- 235000013330 chicken meat Nutrition 0.000 description 36
- 102000004169 proteins and genes Human genes 0.000 description 33
- 239000013612 plasmid Substances 0.000 description 31
- 102000043276 Oncogene Human genes 0.000 description 29
- 238000012054 celltiter-glo Methods 0.000 description 28
- 230000009257 reactivity Effects 0.000 description 28
- 238000003556 assay Methods 0.000 description 24
- 239000012634 fragment Substances 0.000 description 24
- 238000011081 inoculation Methods 0.000 description 24
- 230000003321 amplification Effects 0.000 description 22
- 238000003199 nucleic acid amplification method Methods 0.000 description 22
- 238000001890 transfection Methods 0.000 description 21
- 230000037452 priming Effects 0.000 description 20
- 229940024606 amino acid Drugs 0.000 description 18
- 150000001413 amino acids Chemical class 0.000 description 18
- 230000004044 response Effects 0.000 description 18
- 150000007523 nucleic acids Chemical class 0.000 description 17
- 102000039446 nucleic acids Human genes 0.000 description 16
- 108020004707 nucleic acids Proteins 0.000 description 16
- 230000001131 transforming effect Effects 0.000 description 16
- 206010006187 Breast cancer Diseases 0.000 description 15
- 108010058765 Oncogene Protein pp60(v-src) Proteins 0.000 description 15
- 230000012010 growth Effects 0.000 description 15
- 108020004999 messenger RNA Proteins 0.000 description 14
- 230000006698 induction Effects 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 210000004881 tumor cell Anatomy 0.000 description 13
- 208000026310 Breast neoplasm Diseases 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 238000002255 vaccination Methods 0.000 description 12
- 206010009944 Colon cancer Diseases 0.000 description 11
- 238000011580 nude mouse model Methods 0.000 description 11
- 229920001184 polypeptide Polymers 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 241000894007 species Species 0.000 description 11
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 11
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 10
- 230000005951 type IV hypersensitivity Effects 0.000 description 10
- 239000013598 vector Substances 0.000 description 10
- 229920001817 Agar Polymers 0.000 description 9
- 230000004544 DNA amplification Effects 0.000 description 9
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 9
- 241000699660 Mus musculus Species 0.000 description 9
- 239000008272 agar Substances 0.000 description 9
- 125000003275 alpha amino acid group Chemical group 0.000 description 9
- 108091008819 oncoproteins Proteins 0.000 description 9
- 108700026239 src Genes Proteins 0.000 description 9
- 231100000588 tumorigenic Toxicity 0.000 description 9
- 230000000381 tumorigenic effect Effects 0.000 description 9
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
- 206010061535 Ovarian neoplasm Diseases 0.000 description 8
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- 241000700605 Viruses Species 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 210000003491 skin Anatomy 0.000 description 8
- 230000004614 tumor growth Effects 0.000 description 8
- 241001529936 Murinae Species 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 108020004705 Codon Proteins 0.000 description 6
- 241000713869 Moloney murine leukemia virus Species 0.000 description 6
- 241000714474 Rous sarcoma virus Species 0.000 description 6
- 206010039491 Sarcoma Diseases 0.000 description 6
- 102100030780 Transcriptional activator Myb Human genes 0.000 description 6
- 210000000481 breast Anatomy 0.000 description 6
- 208000029742 colonic neoplasm Diseases 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- WLWIMKWZMGJRBS-UHFFFAOYSA-N primin Chemical compound CCCCCC1=CC(=O)C=C(OC)C1=O WLWIMKWZMGJRBS-UHFFFAOYSA-N 0.000 description 6
- 238000007388 punch biopsy Methods 0.000 description 6
- 238000003153 stable transfection Methods 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 5
- 206010027476 Metastases Diseases 0.000 description 5
- 206010033128 Ovarian cancer Diseases 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 230000001093 anti-cancer Effects 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 102000054766 genetic haplotypes Human genes 0.000 description 5
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 5
- 210000005260 human cell Anatomy 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000002611 ovarian Effects 0.000 description 5
- 238000009877 rendering Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 230000005740 tumor formation Effects 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- 101000583086 Bunodosoma granuliferum Delta-actitoxin-Bgr2b Proteins 0.000 description 4
- 239000012981 Hank's balanced salt solution Substances 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 238000000692 Student's t-test Methods 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000001747 exhibiting effect Effects 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000010899 nucleation Methods 0.000 description 4
- 230000002246 oncogenic effect Effects 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 238000003146 transient transfection Methods 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 108091028690 C-myc mRNA Proteins 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 3
- 101710113436 GTPase KRas Proteins 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 108020005038 Terminator Codon Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 238000000546 chi-square test Methods 0.000 description 3
- 230000000112 colonic effect Effects 0.000 description 3
- 230000009260 cross reactivity Effects 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 239000012531 culture fluid Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 231100000590 oncogenic Toxicity 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 208000003200 Adenoma Diseases 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 101000583080 Bunodosoma granuliferum Delta-actitoxin-Bgr2a Proteins 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102100030708 GTPase KRas Human genes 0.000 description 2
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 2
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 2
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 2
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 2
- 101000869690 Homo sapiens Protein S100-A8 Proteins 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 102100032442 Protein S100-A8 Human genes 0.000 description 2
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 101710101493 Viral myc transforming protein Proteins 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000019771 cognition Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 108700020302 erbB-2 Genes Proteins 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- YRIZYWQGELRKNT-UHFFFAOYSA-N 1,3,5-trichloro-1,3,5-triazinane-2,4,6-trione Chemical compound ClN1C(=O)N(Cl)C(=O)N(Cl)C1=O YRIZYWQGELRKNT-UHFFFAOYSA-N 0.000 description 1
- 108700027557 4-azo- enkephalin-Leu Proteins 0.000 description 1
- 241000724812 AKT8 retrovirus Species 0.000 description 1
- 241000023308 Acca Species 0.000 description 1
- 208000004804 Adenomatous Polyps Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- VWEWCZSUWOEEFM-WDSKDSINSA-N Ala-Gly-Ala-Gly Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(O)=O VWEWCZSUWOEEFM-WDSKDSINSA-N 0.000 description 1
- 101100274418 Arabidopsis thaliana CID4 gene Proteins 0.000 description 1
- 241000726103 Atta Species 0.000 description 1
- 241000713840 Avian erythroblastosis virus Species 0.000 description 1
- 241000713836 Avian myelocytomatosis virus Species 0.000 description 1
- 241000713842 Avian sarcoma virus Species 0.000 description 1
- 206010004433 Benign ovarian tumour Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010057654 Breast cancer female Diseases 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 125000006414 CCl Chemical group ClC* 0.000 description 1
- 108010069682 CSK Tyrosine-Protein Kinase Proteins 0.000 description 1
- 102000029330 CSK Tyrosine-Protein Kinase Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- XULFJDKZVHTRLG-JDVCJPALSA-N DOSPA trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F.CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)CCNC(=O)C(CCCNCCCN)NCCCN)OCCCCCCCC\C=C/CCCCCCCC XULFJDKZVHTRLG-JDVCJPALSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 102100039788 GTPase NRas Human genes 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- OOFLZRMKTMLSMH-UHFFFAOYSA-N H4atta Chemical compound OC(=O)CN(CC(O)=O)CC1=CC=CC(C=2N=C(C=C(C=2)C=2C3=CC=CC=C3C=C3C=CC=CC3=2)C=2N=C(CN(CC(O)=O)CC(O)=O)C=CC=2)=N1 OOFLZRMKTMLSMH-UHFFFAOYSA-N 0.000 description 1
- 241000713858 Harvey murine sarcoma virus Species 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 1
- 101001030211 Homo sapiens Myc proto-oncogene protein Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000713863 Kirsten murine sarcoma virus Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- FSNCEEGOMTYXKY-JTQLQIEISA-N Lycoperodine 1 Natural products N1C2=CC=CC=C2C2=C1CN[C@H](C(=O)O)C2 FSNCEEGOMTYXKY-JTQLQIEISA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 101150039798 MYC gene Proteins 0.000 description 1
- 206010027457 Metastases to liver Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100293199 Mus musculus Myc gene Proteins 0.000 description 1
- 101710150912 Myc protein Proteins 0.000 description 1
- 206010051141 Myeloblastoma Diseases 0.000 description 1
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 description 1
- YFONKFDEZLYQDH-OPQQBVKSSA-N N-[(1R,2S)-2,6-dimethyindan-1-yl]-6-[(1R)-1-fluoroethyl]-1,3,5-triazine-2,4-diamine Chemical compound C[C@@H](F)C1=NC(N)=NC(N[C@H]2C3=CC(C)=CC=C3C[C@@H]2C)=N1 YFONKFDEZLYQDH-OPQQBVKSSA-N 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108010053291 Oncogene Protein v-akt Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 101100271190 Plasmodium falciparum (isolate 3D7) ATAT gene Proteins 0.000 description 1
- 108010045717 Proto-Oncogene Proteins c-akt Proteins 0.000 description 1
- 102000005765 Proto-Oncogene Proteins c-akt Human genes 0.000 description 1
- 108010087705 Proto-Oncogene Proteins c-myc Proteins 0.000 description 1
- 102000009092 Proto-Oncogene Proteins c-myc Human genes 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 101710187995 Transcriptional activator Myb Proteins 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 108010049024 Viral Oncogene Proteins Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 229940030156 cell vaccine Drugs 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 230000002089 crippling effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 230000007773 growth pattern Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008073 immune recognition Effects 0.000 description 1
- 230000002998 immunogenetic effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 108700024542 myc Genes Proteins 0.000 description 1
- GWUSZQUVEVMBPI-UHFFFAOYSA-N nimetazepam Chemical compound N=1CC(=O)N(C)C2=CC=C([N+]([O-])=O)C=C2C=1C1=CC=CC=C1 GWUSZQUVEVMBPI-UHFFFAOYSA-N 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100001221 nontumorigenic Toxicity 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000006548 oncogenic transformation Effects 0.000 description 1
- 201000008016 ovarian benign neoplasm Diseases 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000001566 pro-viral effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108700042226 ras Genes Proteins 0.000 description 1
- 108010014186 ras Proteins Proteins 0.000 description 1
- 102000016914 ras Proteins Human genes 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000013515 script Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 208000019694 serous adenocarcinoma Diseases 0.000 description 1
- 208000004548 serous cystadenocarcinoma Diseases 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000003614 tolerogenic effect Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Un immunogène cellulaire est destiné à immuniser un hôte contre les effets du produit d'un proto-oncogène cible, la surexpression du proto-oncogène cible étant associée à une malignité. L'immunogène cellulaire comprend des cellules hôtes ayant été transfectées avec au moins un transgène reconstruit comprenant un transgène parent du proto-oncogène cible et un promoteur puissant destiné à entraîner l'expression du transgène dans les cellules transfectées. Le transgène code un produit génique induisant l'immuno-réactivité de l'hôte chez des auto-déterminants de l'hôte du produit du gène du proto-oncogène cible. Le transgène peut comprendre, par exemple, un ADN d'oncogène rétroviral mutant ou de type sauvage parent du proto-oncogène cible, ou un ADN de proto-oncogène mutant ou de type sauvage d'une espèce différente des deux espèces d'hôtes. L'immunogène cellulaire peut être préparé à partir de cellules hôtes biopsiées, par exemple des fibroblastes de la peau, lesquelles sont transfectées de manière stable ou transitoire avec le transgène reconstruit contenant le transgène parent. Les cellules hôtes transfectées avec le transgène reconstruit parent sont ensuite renvoyées dans le corps de l'hôte afin d'obtenir une expression dudit transgène parent chez l'hôte.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1026296P | 1996-01-19 | 1996-01-19 | |
| US60/010,262 | 1996-01-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2241952A1 true CA2241952A1 (fr) | 1997-07-24 |
Family
ID=21744913
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002241952A Abandoned CA2241952A1 (fr) | 1996-01-19 | 1997-01-13 | Immunogenes cellulaires utiles en tant que vaccins contre le cancer |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0923284A4 (fr) |
| JP (1) | JP2001501909A (fr) |
| AU (1) | AU717356B2 (fr) |
| CA (1) | CA2241952A1 (fr) |
| WO (1) | WO1997025860A1 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4981999A (en) * | 1998-07-24 | 2000-02-14 | Allegheny University Of The Health Sciences | Allogeneic cellular immunogens useful as cancer vaccines |
| US20020137683A1 (en) * | 2000-01-03 | 2002-09-26 | Hogan Kevin T. | C-ski oncogene-derived peptides for prevention, treatment, and diagnosis of cancer |
| US9068234B2 (en) | 2003-01-21 | 2015-06-30 | Ptc Therapeutics, Inc. | Methods and agents for screening for compounds capable of modulating gene expression |
| US8426194B2 (en) | 2003-01-21 | 2013-04-23 | Ptc Therapeutics, Inc. | Methods and agents for screening for compounds capable of modulating VEGF expression |
| US8460864B2 (en) | 2003-01-21 | 2013-06-11 | Ptc Therapeutics, Inc. | Methods for identifying compounds that modulate untranslated region-dependent gene expression and methods of using same |
| CA2546363A1 (fr) * | 2003-11-17 | 2005-06-02 | Anuradha Mehta | Procedes et agents de criblage de composes capables de moduler l'expression de her2 |
| US8283115B1 (en) | 2007-06-20 | 2012-10-09 | Ptc Therapeutics, Inc. | Methods of screening for compounds for treating muscular dystrophy using UTRN mRNA translation regulation |
| US8283116B1 (en) | 2007-06-22 | 2012-10-09 | Ptc Therapeutics, Inc. | Methods of screening for compounds for treating spinal muscular atrophy using SMN mRNA translation regulation |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE302854T1 (de) * | 1993-01-26 | 2005-09-15 | Univ Pennsylvania | Zusammensetzungen und verfahren zur verabreichung von genetischem material |
| US5593972A (en) * | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
-
1997
- 1997-01-13 JP JP09526124A patent/JP2001501909A/ja active Pending
- 1997-01-13 WO PCT/US1997/000582 patent/WO1997025860A1/fr not_active Application Discontinuation
- 1997-01-13 EP EP97902934A patent/EP0923284A4/fr not_active Withdrawn
- 1997-01-13 AU AU16992/97A patent/AU717356B2/en not_active Ceased
- 1997-01-13 CA CA002241952A patent/CA2241952A1/fr not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU717356B2 (en) | 2000-03-23 |
| JP2001501909A (ja) | 2001-02-13 |
| AU1699297A (en) | 1997-08-11 |
| EP0923284A4 (fr) | 2003-03-26 |
| WO1997025860A1 (fr) | 1997-07-24 |
| EP0923284A1 (fr) | 1999-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4205572B2 (ja) | 子宮頸がんの治療 | |
| Lachman et al. | DNA vaccination against neu reduces breast cancer incidence and metastasis in mice | |
| PT2155243E (pt) | Composição e métodos compreendendo os antigénios klk3, psca ou folh1 | |
| US7662586B2 (en) | Synthetic gene encoding human epidermal growth factor 2/neu antigen and uses thereof | |
| EA011557B1 (ru) | Конструкции нуклеиновых кислот | |
| CN107073094A (zh) | 表达异源性抗原融合蛋白的重组李斯特菌菌株及其使用方法 | |
| CN106061509B (zh) | 编码端粒酶的dna疫苗 | |
| US20110027311A1 (en) | Combination of protein vaccine and mesenchymal stem cells for treating cancer | |
| CA2241952A1 (fr) | Immunogenes cellulaires utiles en tant que vaccins contre le cancer | |
| CN110408634A (zh) | 一种非整合李斯特菌疫苗及抗肿瘤免疫应答方法 | |
| EP1572231A2 (fr) | Immunotherapie anticancereuse | |
| JP2007523610A (ja) | 癌胎児抗原をコードする合成遺伝子およびその使用 | |
| US8389494B2 (en) | p185neu-encoding DNA and therapeutical uses thereof | |
| WO1997025860A9 (fr) | Immunogenes cellulaires utiles en tant que vaccins contre le cancer | |
| US6365151B1 (en) | Cellular immunogens comprising cognate proto-oxogenes | |
| ES2634256T3 (es) | Composiciones innovadoras y usos de las mismas | |
| EP1100544A1 (fr) | Immunogenes cellulaires allogeniques utiles comme vaccins contre le cancer | |
| JP2006525787A (ja) | アカゲザルＨＥＲ２／ｎｅｕ、これをコードするヌクレオチド及びその使用 | |
| JP2007511534A (ja) | 抗腫瘍免疫の相乗的誘導のための組成物および方法 | |
| CN111334521B (zh) | 一种提高非整合减毒李斯特菌外源抗原蛋白表达的方法 | |
| Chen et al. | A novel DNA vaccine containing 4 mimicry epitopes for gastric cancer | |
| US20060286114A1 (en) | Synthetic gene encoding rhesus monkey carcinoembryonic antigen and uses thereof | |
| CA2217491A1 (fr) | Agents immunogenes polynucleotidiques | |
| Penichet et al. | A murine B cell lymphoma expressing human HER2/neu undergoes spontaneous tumor regression and elicits antitumor immunity | |
| Pilon et al. | Recombinant Breast Cancer Vaccines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |